Aquatic Capital Management’s ImmunityBio IBRX Stock Holding History

Aquatic Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-400	Closed	-$2K	–	1373
2022 Q1	$2K	Buy	+400	New	+$2.45K	﹤0.01%	963

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Aquatic Capital Management's IBRX Position: Q2 2022 in Review

Aquatic Capital Management sold out of ImmunityBio (IBRX) in Q2 2022, closing a stake of 400 shares — an estimated $2K sold.

Aquatic Capital Management first reported a position in IBRX in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 131 funds tracked by Wall St. Rank hold IBRX as of Q2 2022.

Aquatic Capital Management reported no remaining ImmunityBio position as of Q2 2022 after selling out during the quarter.
Aquatic Capital Management sold 400 ImmunityBio shares in Q2 2022, an estimated $2K.
Aquatic Capital Management first reported a position in ImmunityBio in Q1 2022 and held it in 1 quarter.
Aquatic Capital Management's ImmunityBio position peaked at $2K in Q1 2022.
131 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2022.

Based on Aquatic Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.